These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29191358)

  • 41. [Radiotherapy for local disease in metastatic prostate cancer.].
    Cambeiro M; Calvo FA
    Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
    King CR; Brooks JD; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
    Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R
    Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
    Robin TP; Raben D; Schefter TE
    Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
    Jackson WC; Dess RT; Litzenberg DW; Li P; Schipper M; Rosenthal SA; Chang GC; Horwitz EM; Price RA; Michalski JM; Gay HA; Wei JT; Feng M; Feng FY; Sandler HM; Wallace RE; Spratt DE; Hamstra DA
    Pract Radiat Oncol; 2018; 8(1):40-47. PubMed ID: 29304991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
    Lischalk JW; Kaplan ID; Collins SP
    Cancer J; 2016; 22(4):307-13. PubMed ID: 27441752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].
    Blanchard P; Foulon S; Louvel G; Habibian M; Fizazi K
    Cancer Radiother; 2017 Oct; 21(6-7):491-494. PubMed ID: 28869198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
    De Bleser E; Tran PT; Ost P
    Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic body radiotherapy for prostate cancer.
    Henderson DR; Tree AC; van As NJ
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):270-9. PubMed ID: 25707911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
    Francolini G; Porreca A; Facchini G; Santini D; Bruni A; Simoni N; Trovò M; Osti MF; Fornarini G; Sisani M; Di Cataldo V; Detti B; Garlatti P; Bertini N; Serni S; Minervini A; Livi L
    Med Oncol; 2023 Dec; 41(1):39. PubMed ID: 38157111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic body radiation therapy for liver metastases in oligometastatic disease.
    Jaksic N; Modesto A; Meillan N; Bordron A; Michalet M; Riou O; Lisbona A; Huguet F
    Cancer Radiother; 2024 Feb; 28(1):75-82. PubMed ID: 37865603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence: A Meta-analysis.
    Viani GA; Arruda CV; Hamamura AC; Faustino AC; Freitas Bendo Danelichen A; Guimarães FS
    Am J Clin Oncol; 2020 Feb; 43(2):73-81. PubMed ID: 31809327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.
    Seymour ZA; Chang AJ; Zhang L; Kirby N; Descovich M; Roach M; Hsu IC; Gottschalk AR
    Pract Radiat Oncol; 2015; 5(5):e465-e472. PubMed ID: 25795252
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.